US FDA Regulatory Roundup: Ceba-Tek GMP Warning, Altaire Expands Recall
Executive Summary
GMP violations FDA warned Ceba-Tek about following an inspection in January and February include problems agency officials also noted in 2014 and 2015; Altaire Pharmaceuticals recalls of ophthalmic products due to lack of sterility assurance passes 500 lots, including 28 of Clear Eyes announced July 16.
You may also be interested in...
Clear Eyes Recall Adds Clarity To Extent Of Impact From Altaire Sterility Concerns
Number of containers recalled varies from nearly 6.7m bottles of Clear Eyes Redness Relief to 1,752 bottles of brand's Maximum Itchy Eye Relief. Updates to FDA database also include recalls of private label/store brand OTCs as agency finds more problems at manufacturers providing drugs for drug store chains, other retailers and distributors.
US FDA Regulatory Roundup: Ecometrics GMP Warning, Altaire Ophthalmic Recalls
Contract manufacturer Ecometics may have distributed adulterated OTC drugs due to inadequate removal of residues from manufacturing equipment it also uses to make insect repellent, FDA says; and Altaire Pharmaceuticals expands its recall of OTC and Rx ophthalmic products due to a lack of sterility assurance.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”